JNJ Johnson & Johnson

135.22
-0.16  -0%
Previous Close 135.38
Open 135.02
Price To book 5.05
Market Cap 362930443220
Shares 2,683,999,728
Volume 4,898,505
Short Ratio 2.96
Av. Daily Volume 5,274,460

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approval announced August 2, 2017.
Imbruvica
Second-line Chronic graft-versus-host disease (GVHD)
PDUFA date under priority review October 28, 2017.
XARELTO (rivaroxaban)
Reduce the Risk of Recurrent Venous Thromboembolism (VTE)
Phase 3 data presented at ASCO June 3, 2017 - PFS 33 months. sNDA filing announced September 14, 2017.
ZYTIGA (abiraterone acetate) - LATITUDE
metastatic hormone-naïve prostate cancer (mHNPC)
Phase 3 trial stopped early due to positive efficacy - February 8, 2017.
XARELTO (rivaroxaban)
Coronary Artery Disease or Peripheral Artery Disease
Cardiovascular Outcomes trial data released June 12, 2017 - 14% reduction in the risk of the composite primary endpoint of CV mortality.
INVOKANA CANVAS
Type 2 diabetes
Phase 3 trial to be completed in 2018.
STELARA (USTEKINUMAB)
Ulcerative colitis
Phase 3 data due 2019.
INVOKANA - CREDENCE
Diabetic Kidney Disease
Primary endpoint of non inferiority met - December 19, 2016. NDA filing announced June 5, 2017. Priority review requested - estimate PDUFA December 5, 2017 (6 month timeline) assuming priority review granted.
Rilpivirine and Dolutegravir
HIV
Phase 3 data likely due 2019.
DARZALEX (Daratumumab)
Frontline multiple myeloma (transplant)
Phase 3 data likely due 2018.
DARZALEX (Daratumumab)
Frontline multiple myeloma (non-transplant)
Phase 2 clinical hold lifted Nov 2014. Phase 2 initiated September 2015. Internal review conducted September 2016. Low dose discontinued, high dose enrollment suspended. Further review conducted April 2017 - further development pending FDA feedback and longer term data.
Imetelstat - IMbarkStudy
Myelofibrosis
Announced mid-January 2016 that Phase 2 dosing has been initiated. Internal reviews conducted September 2016 and April 2017, trial to continue as planned. Phase 3 part of trial to be initiated 4Q 2017 pending FDA feedback.
Imetelstat - IMerge Study
Myelodysplastic syndromes
Phase 3 ongoing. Data and regulatory filings likely due 2018.
Esketamine
Treatment resistant depression
sNDA filing announced September 26, 2017. Priority Review. Approved January 19, 2017.
Imbruvica
Marginal zone lymphoma
sBLA filing announced December 15, 2016. PDUFA estimate October 15, 2017.
STELARA (USTEKINUMAB)
Plaque psoriasis
sBLA filing announced December 21, 2016. PDUFA date estimate October 21, 2017.
SIMPONI ARIA
Psoriatic arthritis (PsA)
sBLA filing announced December 21, 2016. PDUFA date estimate October 21, 2017.
SIMPONI ARIA
Ankylosing Spondylitis
Approval announced July 13, 2017.
Guselkumab
Plaque psoriasis
BLA filing announced September 23, 2016. PDUFA estimate September 23, 2017. Advisory Committee Meeting August 2, 2017 voted 12-1 against that safety data is adequate to support approval. 13-0 in favor of efficacy.
Sirukumab
Rheumatoid arthritis
Approval announced June 16, 2017 - note: submitted by Janssen Biotech, Inc.
DARZALEX (Daratumumab) + pomalidomide and dexamethasone
Relapsed or refractory multiple myeloma